Immatics
Miriam Meyer joined Immatics in September 2009 and is Senior Director and Head of Regulatory Affairs in Europe.
Miriam began her carrier at Hexal AG in Holzkirchen where she started with Regulatory Affairs for classical generic products and later became the regulatory lead for the development of Hexal’s first biosimilar medicinal product. Thereafter, Miriam moved to GPC Biotech GmbH where she gained experience in the field of Regulatory Affairs for small molecules and biological products developed for cancer therapies. Since 2009 Miriam has been working for Immatics and signs responsible for strategic and operational Regulatory Affairs for the entire Immatics product pipeline developed in the EU.
Miriam completed her Ph.D. thesis in Molecular biology in the lab of Axel Ullrich at the Max-Planck-Institute of Biochemistry in Martinsried. She holds a Master of Drug Regulatory Affairs from the University Bonn and a Diploma in food chemistry from the University Kaiserslautern.
This person is not in any offices
Immatics
9 followers
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.